loading
Precedente Chiudi:
$3.34
Aprire:
$3.35
Volume 24 ore:
271.15K
Relative Volume:
0.35
Capitalizzazione di mercato:
$142.61M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-1.2556
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+8.44%
1M Prestazione:
-7.99%
6M Prestazione:
-61.03%
1 anno Prestazione:
-85.63%
Intervallo 1D:
Value
$3.24
$3.46
Intervallo di 1 settimana:
Value
$3.11
$3.74
Portata 52W:
Value
$2.235
$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Nome
4 D Molecular Therapeutics Inc
Name
Telefono
(510) 505-2680
Name
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Name
Dipendente
227
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
FDMT's Discussions on Twitter

Confronta FDMT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
3.34 142.61M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-13 Downgrade BMO Capital Markets Outperform → Market Perform
2024-11-21 Iniziato Morgan Stanley Underweight
2024-09-23 Downgrade Cantor Fitzgerald Overweight → Neutral
2024-04-15 Iniziato Barclays Overweight
2024-02-07 Ripresa Goldman Buy
2023-10-26 Iniziato RBC Capital Mkts Outperform
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-10-18 Aggiornamento Leerink Partners Market Perform → Outperform
2023-07-05 Iniziato Chardan Capital Markets Buy
2023-01-30 Iniziato BMO Capital Markets Outperform
2022-11-18 Iniziato H.C. Wainwright Buy
2022-11-15 Aggiornamento Goldman Neutral → Buy
2022-08-12 Downgrade SVB Leerink Outperform → Mkt Perform
2022-06-22 Iniziato Jefferies Buy
2022-01-04 Iniziato SVB Leerink Outperform
2021-01-05 Iniziato BofA Securities Buy
2021-01-05 Iniziato Evercore ISI Outperform
2021-01-05 Iniziato Goldman Neutral
Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

pulisher
Apr 28, 2025

X-linked retinitis pigmentosa Pipeline Analysis and Clinical - openPR.com

Apr 28, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Geode Capital Management LLC - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

4D Molecular Therapeutics Inc [FDMT] Shares Rise 0.59 % on Wednesday - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals Clinical Trials, Prevalence, Medication, Revenue, Statistics, Pipeline and Companies by DelveInsight - The Globe and Mail

Apr 24, 2025
pulisher
Apr 24, 2025

American Express Just Delivered Fantastic News for Investors. Here's Why the Warren Buffett Stock Is a Buy Now. - The Globe and Mail

Apr 24, 2025
pulisher
Apr 24, 2025

Orion Mine Finance selling at Allied Gold (AAUC) - The Globe and Mail

Apr 24, 2025
pulisher
Apr 23, 2025

How should investors view 4D Molecular Therapeutics Inc (FDMT)? - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st

Apr 22, 2025
pulisher
Apr 21, 2025

Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & Gilead Sciences (NASDAQ:GILD) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 20, 2025
pulisher
Apr 18, 2025

What is Leerink Partnrs’ Estimate for FDMT FY2026 Earnings? - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com

Apr 15, 2025
pulisher
Apr 15, 2025

Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com

Apr 15, 2025
pulisher
Apr 15, 2025

American Century Companies Inc. Acquires 4,429 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Purchases 11,089 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

8,600 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by KLP Kapitalforvaltning AS - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Apr 11, 2025
pulisher
Apr 10, 2025

4D Molecular Therapeutics, Inc. (FDMT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 09, 2025

Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Raymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 07, 2025
pulisher
Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 30, 2025
pulisher
Mar 27, 2025

PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 27, 2025
pulisher
Mar 24, 2025

Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - The AM Reporter

Mar 24, 2025
pulisher
Mar 21, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts - The AM Reporter

Mar 20, 2025
pulisher
Mar 20, 2025

Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World

Mar 20, 2025
pulisher
Mar 16, 2025

M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 16, 2025
pulisher
Mar 13, 2025

Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World

Mar 07, 2025

4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Capitalizzazione:     |  Volume (24 ore):